Fresenius SE & Co. KGaA

FRE

DE0005785604

Healthcare Facilities & Services

Real-time Estimate Tradegate Other stock markets 07:55:59 2024-05-20 am EDT			5-day change	1st Jan Change
27.9 ^EUR	-0.13%		-2.72%	-0.64%

08:21am	JPMorgan raises target for Fresenius SE to 37.60 euros - 'Neutral'	DP
07:52am	FRESENIUS SE : JP Morgan remains Neutral	ZD

FRESENIUS SE : Warburg Research reaffirms its Buy rating

May 08, 2024 at 08:29 am EDT

In a research note published by Christian Ehmann, Warburg Research advises its customers to buy the stock. The target price is unchanged at EUR 41.

Latest news about Fresenius SE & Co. KGaA

JPMorgan raises target for Fresenius SE to 37.60 euros - 'Neutral'	02:21am	DP
FRESENIUS SE : JP Morgan remains Neutral	01:52am	ZD
What does the new atlas mean for the 'hospital jungle'?	May. 17	DP
Moody’s Revises Outlook on Fresenius Medical Care to Stable from Negative	May. 17	MT
Launch of new quality atlas for hospitals	May. 17	DP
Moody’s Affirms Fresenius' Rating, Outlook on Improving Profitability	May. 16	MT
Union demands Lauterbach approach the federal states on hospital reform	May. 16	DP
Dobrindt demands approach to federal states on hospital reform	May. 16	DP
Lauterbach's 'revolution' for clinics on the way	May. 15	DP
Cabinet launches hospital reform	May. 15	DP
Cabinet to get hospital reform underway	May. 15	DP
FRESENIUS SE : Receives a Buy rating from DZ Bank	May. 14	ZD
FRESENIUS SE : Jefferies reiterates its Buy rating	May. 14	ZD
Global markets live: Pfizer, Chevron, Amazon, Booking, Apple, Novavax, SoftBank...	May. 13
FRESENIUS SE : Barclays gives a Buy rating	May. 13	ZD
FRESENIUS SE : Berenberg gives a Buy rating	May. 13	ZD
Fresenius Medical sees up to 2% US dialysis growth by year-end	May. 11	RE
European Equities Traded in the US as American Depositary Receipts Trend Higher in Friday Trading; End Week Up Nearly 3%	May. 10	MT
FRESENIUS : Preparing for a strong(er) future performance	May. 10
FRESENIUS SE : Deutsche Bank keeps its Buy rating	May. 09	ZD
Health Care Slips as Defensive Investors Rotate to Utilities - Health Care Roundup	May. 08	DJ
Home REIT cuts borrowings, Genflow shares restored	May. 08	AN
European Equities Traded in the US as American Depositary Receipts Trend Modestly Higher in Wednesday Trading	May. 08	MT
Fresenius becomes more optimistic thanks to subsidiary Kabi - exit from Vamed	May. 08	DP
UBS rates Fresenius SE as 'Buy' - Target 34 euros	May. 08	DP

Fresenius SE & Co. KGaA specializes in designing, producing, and selling medical drugs, equipment, and devices used in clinical hospitalization and at home. Net sales break down by activity as follows: - dialysis treatment (46.9%; Fresenius Medical Care): sales of equipment for hemodialysis, pediatric dialysis, peritoneal dialysis, dialysis services, etc.; - hospital administration and engineering (34.1%; Fresenius Vamed and Fresenius Helios): management of technical facilities and medical equipment, hospital management, design and production of medical equipment for the pharmaceutical sector, etc.; - perfusion and clinical nutrition (19%; Fresenius Kabi): sales of parenteral and oral nutrition products, perfusion and vascular filling equipment, transfusion materials, generic injectable products, home medical assistance services in the areas of perfusion, nutrition, and oxygen therapy, etc. Net sales are distributed geographically as follows: Europe (43.8%), North America (39.4%), Asia/Pacific (10.1%), Latin America (5.4%) and Africa (1.3%).

Sector

Healthcare Facilities & Services

Calendar

2024-07-30 - Q2 2024 Earnings Call

Related indices

STOXX EUROPE 600 (EUR) , DAX

More about the company

Income Statement Evolution

More financial data

Analysis / Opinion

FRESENIUS : Preparing for a strong(er) future performance

May 10, 2024 at 03:46 am EDT

More Strategies

Ratings for Fresenius SE & Co. KGaA

Trading Rating

Investor Rating

ESG Refinitiv

A-

More Ratings

Analysts' Consensus

Sell

Buy

Mean consensus

BUY

Number of Analysts

Last Close Price

27.94 EUR

Average target price

36.72 EUR

Spread / Average Target

+31.44%

Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Other Healthcare Facilities & Services

	1st Jan change	Capi.
FRESENIUS SE & CO. KGAA	-0.64%	17.11B
HCA HEALTHCARE, INC.	+19.28%	84.56B
CVS HEALTH CORPORATION	-26.95%	72.41B
DR. SULAIMAN AL HABIB MEDICAL SERVICES GROUP COMPANY	+2.04%	27.73B
LABORATORY CORPORATION OF AMERICA HOLDINGS	-7.35%	17.75B
QUEST DIAGNOSTICS INCORPORATED	+4.69%	16.03B
REDE D'OR SÃO LUIZ S.A.	+8.14%	13.72B
NATERA, INC.	+69.96%	13.07B
FRESENIUS MEDICAL CARE AG	+6.56%	12.91B
TENET HEALTHCARE CORPORATION	+70.00%	12.55B

Other Healthcare Facilities & Services

Fresenius SE & Co. KGaA

Equities

FRE

DE0005785604

Healthcare Facilities & Services

FRESENIUS SE : Warburg Research reaffirms its Buy rating

Latest news about Fresenius SE & Co. KGaA

Chart Fresenius SE & Co. KGaA

Company Profile

Income Statement Evolution

Analysis / Opinion

Ratings for Fresenius SE & Co. KGaA

Analysts' Consensus

EPS Revisions

Quarterly earnings - Rate of surprise

Sector Other Healthcare Facilities & Services